TEOAE monitoring of Cisplatin induced ototoxicity in guinea pigs: the protective effect of vitamin B treatment☆
Introduction
Cis-diammineedichloroplatinum (Cisplatin, CP) is a chemotherapeutic agent frequently used for the treatment of head and neck neoplasms whose side effects include ototoxicity, nephrotoxicity, bone marrow supression and gastrointestinal disturbances. The incidence of ototoxicity due to CP treatment was reported to vary between 4 and 50% [1], [2], [3]. Furthermore, high frequency audiometry has shown that virtually all cases treated with CP suffer from some sort of sensorineural hearing loss [4].
CP ototoxicity was thought to result from increased amounts of toxic free radicals [7], [8], [9] or cell membrane changes leading to a decreased intracellular calcium content [10], [11], [12]. The clinical picture includes a moderate degree of high frequency sensorineural hearing loss accompanied by tinnitus. The hearing loss is generally bilateral, progressive and irreversible in nature; rarely unilateral hearing losses and temporary threshold shifts may be encountered [1], [3].
Human and animal experiments have revealed that the primary target affected by CP ototoxicity is the outer hair cell (OHC) population located in the basal and middle turns of the cochlea [1], [4], [13]. The loss of OHC function leads to a disturbance in the mechanoelectrical transduction of sound, thereby negatively affecting the sensitivity and frequency selectivity of the cochlea [14], [15].
Various agents were previously used clinically and experimentally in an effort to decrease or prevent CP induced ototoxicity. These include methylthiobenzoic acid [7], phosphomycine [16], thiosulphate [17], glutathion [18], retinoic acid [19] and pantothenic acid [10]. In this study, the effect of vitamin B complex treatment on CP induced ototoxicity in guinea pigs was evaluated by using transient evoked otoacoustic emissions (TEOAE).
Section snippets
Material and methods
Thirteen adult guinea pigs were included in the study which was approved by the local ethical committee. One animal was lost due to a self-induced wound infection, another one was excluded due to a negative pretreatment TEOAE response, with a total number of 11 guinea pigs studied. All animals were put in separate cages with free access to food and water during the investigation. The ears of all animals were inspected otomicroscopically, cleaned of wax and debris, verifying that there were no
Results
The click stimuli used in our study had flat acoustic spectrums for frequencies between 0.5 and 5 kHz. The mean test duration was 57.86±14.74 s (range 21–122 s). The mean stimulus intensity was 75.4±3.8 dB pe SPL (range 69–87 dB pe SPL). The mean response amplitude was 8.6±4.1 dB pe SPL (range 1.4–26.5 dB pe SPL). TEOAE responses recorded from 22 ears of 11 guinea pigs before drug administrations showed that the responses with maximum amplitude were originated from the mid-frequency region (
Discussion
Otoacoustic emission (OAE) testing is a simple noninvasive test which specifically reflects the functional integrity of the cochlear mechanical elements. TEOAE elicited in response to a click stimulus can enable detection of an injury along the whole length of the cochlea. It could be judged that there is normal cochlear activity throughout a long cochlear segment if the response spectrum involves a wide frequency width. On the other hand, a narrow TEOAE response spectrum indicates a relatively
References (29)
- et al.
Changes in otoacoustic emissions and auditory brain stem response after cis-platinum exposure in gerbils
Otolaryngol. Head Neck Surg.
(1997) - et al.
Up-regulation of adenosine receptors in the cochlea by cisplatin
Hearing Res.
(1997) - et al.
Calcium antagonism and reversibility of gentamycin induced loss of cochlear microphonics in the guinea pigs
Hearing Res.
(1982) - et al.
Ototoxicity of cis-dichlorodiammine platinum (II) in guinea pigs
Am. J. Otolaryngol.
(1983) - et al.
The ototoxic effect of cisplatin on guinea pigs in relation to dosage
Hearing Res.
(1989) - et al.
Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster
Otolaryngol. Head Neck Surg.
(1997) - et al.
Cisplatin-induced ototoxicity; electrophysiological evidence of spontaneous recovery in the albino guinea pig
Hearing Res.
(1997) - et al.
Acoustic distortion products can be used to monitor the effects of chronic gentamycine treatment
Hearing Res.
(1989) - et al.
Cisplatinum ototoxicity: clinical experience and temporal bone histopathology
Laryngoscope
(1983) - et al.
High-dose cisplatin treatment: hearing loss and plasma concentrations
Laryngoscope
(1990)
Ototoxicity of low- and moderate-dose cisplatin
Cancer
Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing
Laryngoscope
Detection of early ototoxic effect in testicular-cancer patients treated with cisplatin by transiently evoked otoacoustic emission: a pilot study
Oncology
Protection by 4-methylthiobenzoic acid against cisplatin-induced ototoxicity: antioxidant system
Pharmacol. Toxicol.
Cited by (25)
Dexamethasone-loaded chitosan-based genipin-cross-linked hydrogel for prevention of cisplatin induced ototoxicity in Guinea pig model
2019, International Journal of Pediatric OtorhinolaryngologyCitation Excerpt :In this study, IP administration of a single dose of 14 mg/kg CP effectively generated CP ototoxicity in a guinea pig model. A wide variety of methods have been described in the literature to establish CP ototoxicity in guinea pigs, with a single dose of between 10 and 20 mg/kg most common [23,24]. However, doses as high as 30 mg/kg have been reported [25].
Assessment of auditory functions in chronic hepatitis C patients treated by sofosbuvir
2018, Journal of OtologyCitation Excerpt :The sensitivity of OAEs as an early indicator of cochlear dysfunction in patients receiving ototoxic agents has been recorded. Reduction in OAE amplitude, as an early sign of an ototoxic effect, may be attributed to outer hair cell (OHC) damage (Youssef, 1998; Guneri et al., 2001). Some studies have suggested the possibility of early detection of hearing loss by testing evoked otoacoustic emissions (EOAE) (Sulaiman et al., 2014).
Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity – Exploring the armoury of obscurity
2018, Saudi Pharmaceutical JournalDietary vitamin intake correlates with hearing thresholds in the older population: The Korean National Health and Nutrition Examination Survey
2014, American Journal of Clinical NutritionThe role of apoptosis in cisplatin-induced ototoxicity in rats
2009, Brazilian Journal of OtorhinolaryngologyCitation Excerpt :The antineoplastic action mechanism is associated to the selective and persistent inhibition of the deoxyribonucleic acid synthesis (DNA)3. Its side effects include ototoxicity, kidney toxicity, medullar suppression and gastrointestinal disorders4. These types of toxicity can impact treatment - as it reduces the chemotherapy dosage, frequency and duration for many patients5.
Distortion-product otoacoustic emissions and auditory brainstem responses sensitivity assessment in cisplatin-induced ototoxicity in rats
2009, Brazilian Journal of OtorhinolaryngologyCitation Excerpt :Cisplatin (cis-diamine-dichloroplatinum – CDDP) is a chemothepeutic drug frequently used to treat many types of cancer, especially those in the head and neck1. Its side effects include ototoxicity, nephrotoxicity, medullary suppression and GI disorders2. These types of toxicity can interfere with treatment as it reduces treatment dosage, frequence and duration in many patients3.
- ☆
Presented as a poster at Otology 2000: Achievements and Perspectives, 15–19 August 1999, University of Zurich, Switzerland.